Pfizer Inc.: Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
Positive pivotal top-line data demonstrates 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, can likely help protect against all 20 vaccine serotypes in three-dose series
Annaliesa Anderson Pediatric Program Exchange Commission European Commission Decision European Medicines Agency Vaccine Research
Source: finanznachrichten.de